SCHEMBL2330337

SCHEMBL2330337

[c]1ccc(-c2cccc(-c3cc[c]cc3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
RAB9A P51151 2/20 0.59
ALDH1A1 P00352 3/20 0.52
MAPT P10636 2/20 0.52
HPGD P15428 2/20 0.52
POLB P06746 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ASIC3 Q9UHC3 1/20 0.43
CCR1 P32246 2/20 0.37
CCR8 P51685 2/20 0.37
KDM4E B2RXH2 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
HSP90AA1 P07900 2/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
ALPL P05186 1/20 0.37
ALPI P09923 1/20 0.37
ALPG P10696 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715046 0.93 MEN1 (0.73) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL5401267 0.84 ASIC3 (0.67) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL4717453 0.84 MEN1 (0.43) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL714995 0.84 CCR1 (0.60) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL18422915 0.81 CTSS (0.53) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL27932446 0.80 MEN1 (0.53) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL2155077 0.80 BTK (0.45) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL23911682 0.77 MEN1 (0.72) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL23911681 0.77 MEN1 (0.72) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL28268565 0.75 CYP19A1 (0.53) MEN1KMT2ARAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190298841-A1 Nucleic Acid Complexes PROCARTA BIOSYSTEMS LTD (GB) 2019-10-03 US claimed
US-20130059775-A1 Nucleic Acid Complexes PROCARTA BIOSYSTEMS LTD (GB) 2013-03-07 US claimed
EP-2533815-A1 NUCLEIC ACID COMPLEXES Procarta Biosystems Ltd (GB) 2012-12-19 EP claimed
WO-2011098829-A1 NUCLEIC ACID COMPLEXES PROCARTA BIOSYSTEMS LTD (GB) 2011-08-18 WO claimed
US-20190298841-A1 Nucleic Acid Complexes PROCARTA BIOSYSTEMS LTD (GB) 2019-10-03 US disclosed
US-10350299-B2 Nucleic acid complexes PROCARTA BIOSYSTEMS LTD. (GB) 2019-07-16 US disclosed
US-20170340745-A1 NUCLEIC ACID COMPLEXES PROCARTA BIOSYSTEMS LTD. (GB) 2017-11-30 US disclosed
US-9669101-B2 Nucleic acid complexes PROCARTA BIOSYSTEMS LTD (GB) 2017-06-06 US disclosed
US-9550991-B2 Transcription factor decoys PROCARTA BIOSYSTEMS LTD. (GB) 2017-01-24 US disclosed
EP-2552455-B1 TRANSCRIPTION FACTOR DECOYS PROCARTA BIOSYSTEMS LTD (GB) 2016-12-28 EP disclosed
US-20150196652-A1 NUCLEIC ACID COMPLEXES PROCARTA BIOSYSTEMS LTD (GB) 2015-07-16 US disclosed
US-9024005-B2 Nucleic acid complexes PROCARTA BIOSYSTEMS LTD (GB) 2015-05-05 US disclosed
US-20140274800-A1 TRANSCRIPTION FACTOR DECOYS FOR THE TREATMENT AND PREVENTION OF INFECTIONS CAUSED BY BACTERIA INCLUDING CLOSTRIDIUM DIFFICILE PROCARTA BIOSYSTEMS LTD. (GB) 2014-09-18 US disclosed
WO-2014140581-A1 TRANSCRIPTION FACTOR DECOYS PROCARTA BIOSYSTEMS LTD (GB) 2014-09-18 WO disclosed
US-20130252881-A1 Transcription Factor Decoys PROCARTA BIOSYSTEMS LTD. (GB) 2013-09-26 US disclosed
US-20130059775-A1 Nucleic Acid Complexes PROCARTA BIOSYSTEMS LTD (GB) 2013-03-07 US disclosed
EP-2552455-A2 TRANSCRIPTION FACTOR DECOYS Procarta Biosystems Ltd (GB) 2013-02-06 EP disclosed
EP-2533815-A1 NUCLEIC ACID COMPLEXES Procarta Biosystems Ltd (GB) 2012-12-19 EP disclosed
WO-2011121357-A2 TRANSCRIPTION FACTOR DECOYS PROCARTA BIOSYSTEMS LIMITED (GB) 2011-10-06 WO disclosed
WO-2011098829-A1 NUCLEIC ACID COMPLEXES PROCARTA BIOSYSTEMS LTD (GB) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10350299-B2 Nucleic acid complexes ZFR, SUB1, RELA MEN1 4030/4885KMT2A 1202/4885RAB9A 4212/4885
US-20170340745-A1 NUCLEIC ACID COMPLEXES ZFR, SUB1, RELA MEN1 4030/4885KMT2A 1202/4885RAB9A 4212/4885
US-20190298841-A1 Nucleic Acid Complexes ZFR, SUB1, RELA MEN1 4030/4885KMT2A 1202/4885RAB9A 4212/4885
US-20150196652-A1 NUCLEIC ACID COMPLEXES ZFR, SUB1, RELA MEN1 4030/4885KMT2A 1202/4885RAB9A 4212/4885
US-20130059775-A1 Nucleic Acid Complexes ZFR, SUB1, RELA MEN1 4030/4885KMT2A 1202/4885RAB9A 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.